保密 | 投资责任声明 | 联系我们
Excorp Medical's Bioartificial Liver System comprises a reusable instrument, disposable tubing set and the proprietary, disposable bioartificail reactor.Once approved by regulatory agencies, Excorp Medical expects this breakthrough Bioartificial Liver System technology to be both live-saving and cost effective.Certain drugs or machines are available to substitute temporarily or long-term for many organs in the body…  no comparable substitute has been developed for the liver.The liver is the largest organ in the body and performs a variety of tasks impacting all body systems… as a result liver disease has widespread effects on virtually all other organs.Excorp Medical is currently the only company approved to conduct bioartificial liver human trials within the U.S.Currently patients must receive a liver transplant or endure prolonged hospitalization at great expense to have a chance at survival.Excorp Medical Bioartificial Liver System treatments serve as a bridge to liver regeneration and transplantExcorp Medical has developed a Bioartificial Liver System for the metabolic support of patients with compromised liver function.
Chinese Simplified
简体中文
Chinese Traditional
繁體中文
Arabic
若需更多信息，请点击下方按钮
执行摘要
2009年1月

下载

爱克思科医疗设备有限
公司宣传手册

下载

美国食品及药物管理局（FDA）之指定“孤儿”罕见病药物所享权益

下載

致投资者
新闻
关联单位
出版文章
临床研究
招聘
致投资者
爱克思科医疗设备有限公司成立于1995年11月22日，是一家总部位于美国，并在美国明尼苏达州注册成立的公司 公司及其子公司的近期目标是：在急症肝功能衰竭患者肝脏自我修复，或肝脏移植手术成功之前, 为之提供有效，且性价比极高的临时肝功能支持
本网站提供的信息数据非完整数据，仅供参考；网站内容不包含与爱克思科医疗设备有限公司投资相关的重要信息及风险因素，公司可在不作通知的情况下对其进行更改
本网站所含所有信息都与爱克思科医疗设备有限公司寻求投资无关 若有意进行投资，请参考由爱克思科医疗设备有限公司编制，可代表公司决议的《私募备忘录》《私募备忘录》内容包括本网站未包括的重要信息，并可完全取代本网站所含所有信息数据
©2014 Excorp Medical, Inc.